On the ameliorative potential of Baccharis trimera in an experimental model of pulmonary disease
Abstract
Diabetes mellitus, smoking, and dyslipidemia are more prevalent in patients with chronic obstructive pulmonary disease (COPD), the fourth leading cause of mortality worldwide. This study employed a model of lung disease in Wistar rats that incorporated these three risk factors, and investigated the effects of Baccharis trimera, a widely used medicinal plant, since no previous studies have evaluated its pulmonary effects. The diabetic and dyslipidemic rats were exposed to smoke for 4 weeks and treated with vehicle (C- group), an extract of B. trimera (HEBT), or simvastatin+insulin, for 2 weeks. The bronchoalveolar lavage was performed to evaluate inflammation. The lungs were collected for histopathological and redox state analyses. A decrease in body weight, an increase in oxidative stress, inflammation, and histopathological changes were observed in C- group. HEBT reversed these alterations and had a moderate antiinflammatory effect. Treatment with HEBT present promising effects for COPD.References
1. Agustí A, Hogg JC. Update on the pathogenesis of chronic obstructive pulmonary disease. N Engl J Med. 2019;381:1248–56.
2. Barnes PJ, Stockey RA. COPD: current therapeutic interventions and future approaches. Eur Resp J. 2005;25:1084-1106.
3. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Resp J. 2009;33:1165-85.
4. Lucas-Ramos P, Izquierdo-Alonso JL, Moro JMRG, Bellón-Cano JM, Ancochea-Bermúdez J, Calle-Rubio M, et al. Cardiovascular risk factors in chronic obstructive pulmonary disease: results of the ARCE study. Arch Bronconeumol. 2008;5:233-8.
5. Gold 2020. REPORT 2019. Prevention of Chronic Obstructive Pulmonary Disease: 1–141.
6. Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65:956-62.
7. Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137:1091-97.
8. Sin DD, Man SF. Impact of cancers and cardiovascular disease in chronic obstructive pulmonary disease. Curr Opin in Pulm Med. 2008;14: 115-21.
9. Correa MP. Dicionário das Plantas úteis do Brasil e das exóticas cultivadas. Rio de Janeiro: Imprensa Nacional; 1978. 74 p.
10. Rabelo ACS, Costa DC. A review of biological and pharmacological activities of Baccharis trimera. Chem Biol Interac. 2018;296:65–75.
11. Alonso JR. 1998. Tratado de Fitomedicina - bases clínicas y farmacológicas. Buenos Aires, Argentina: ISIS Ediciones SRL; 1998. 354 p.
12. Verdi LG, Brighente IMC, Pizzolati MG. Gênero Baccharis (Asteraceae): Aspectos químicos, econômicos e biológicos. Quim Nova. 2005;28:85-94.
13. Feijó AM, Bueno MEN, Ceolin T, Linck CL, Schwartz E, Lange C, et al. Plantas medicinais utilizadas por idosos com diagnóstico de Diabetes mellitus no tratamento dos sintomas da doença. Rev Bras Plantas Med. 2012;14:50-56.
14. Lívero FAR, Martins GG, Queiroz Telles JE, Beltrame OC, Petris Biscaia SM, Cavicchiolo Franco CR, et al. 2016. Hydroethanolic extract of Baccharis trimera ameliorates alcoholic fatty liver disease in mice. Chem Biol Interac. 2016;260:22–32.
15. Lívero FAR, Silva LM, Ferreira DM, Galuppo LF, Borato DG, Prando TBL, et al. Baccharis trimera hydroethanolic extract promotes gastroprotection and healing of gastric lesions induced by acute and chronic ethanol consumption. Naunyn Schmiedebergs Arch Pharmacol. 2016;2016:1-16.
16. Barbosa RJ, Silva GR, Cola IM, Kuchler JC, Coelho N, Barboza LN, et al. Promising therapeutic use of Baccharis trimera (Less.) DC. as a natural hepatoprotective agent against hepatic lesions that are caused by multiple risk factors. J Ethnopharmacol. 2020;254:112729.
17. Souza MMQ, Silva GR, Cola IM, Silva AO, Schaedler MI, Guarnier LP, et al. Baccharis trimera (Less.) DC: an innovative cardioprotective herbal medicine against multiple risk factors for cardiovascular disease. J Med Food. 2020;23:676-684.
18. Mendes TC, Silva GR, Silva AO, Schaedler MI, Guarnier LP, Palozi RA, et al. Hepato-and cardioprotective effects of Baccharis trimera (Less.) DC. against multiple risk factors for chronic noncommunicable diseases. An Acad Bras Cienc. 2021;93:e20200899.
19. Sert NP, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biol. 2020;18:7.
20. Kozma RLH, Alves EM, Barbosa-Oliveira VA, Lopes FDTQ, Guardia RC, Buzo HV, et al. A new experimental model of cigarette smoke-induced emphysema in Wistar rats. J Bras Pneumol. 2014;40:46-54.
21. Aebi H. 1984. Catalase in vitro. In: Methods Enzymol. Academic Press. p. 121-6.
22. Gao R, Yuan Z, Zhao Z, Gaob X. Mechanism of pyrogallol autoxidation and determination os superoxide dismutase enzyme activity. Bioelectrochem Bioenerg. 1998;45:41-5.
23. Jiang ZY, Hunt JV, Wolff SP. Ferrous ion oxidation in the presence of xylenol orange for detection of lipid hydroperoxide in low density lipoprotein. Anal Biochem. 1992;202:384-9.
24. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem. 1968;25:192-205.
25. Niemann B, Rohrbach S, Miller MR, Newby DE, Fuster V, Kovacic JC. Oxidative Stress and Obesity, Diabetes, Smoking and Pollution: Part 3 of a 3-Part Series. J Am Coll Cardiol. 2017; 70: 230-51.
26. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. JACC. 2019;74:e177–e 232.
27. Lucas-Ramos P, Izquierdo-Alonso JL, Moro JMRG, Bellón-Cano JM, Ancochea-Bermúdez J, Calle-Rubio M, et al. Cardiovascular risk factors in chronic obstructive pulmonary disease: results of the ARCE study. Arch Bronconeumol. 2008;5:233-8.
Copyright (c) 2022 Saúde e Pesquisa
This work is licensed under a Creative Commons Attribution 4.0 International License.
A submissão de originais para a revista Saúde e Pesquisa implica na transferência da Carta Concessão de Direitos Autorais, pelos autores, dos direitos de publicação digital para a revista após serem informados do aceite de publicação.A Secretaria Editorial irá fornecer da um modelo de Carta de Concessão de Direitos Autorais, indicando o cumprimento integral de princípios éticos e legislação específica. Os direitos autorais dos artigos publicados nesta revista são de direito do autor, com direitos da revista sobre a primeira publicação. Os autores somente poderão utilizar os mesmos resultados em outras publicações, indicando claramente a revista Saúde e Pesquisa como o meio da publicação original. Em virtude de tratar-se de um periódico de acesso aberto, é permitido o uso gratuito dos artigos, principalmente em aplicações educacionais e científicas, desde que citada a fonte. A Saúde e Pesquisa adota a licença Creative Commons Attribution 4.0 International.
A revista se reserva o direito de efetuar, nos originais, alterações de ordem normativa, ortográfica e gramatical, com vistas a manter o padrão culto da língua e a credibilidade do veículo. Respeitará, no entanto, o estilo de escrever dos autores. Alterações, correções ou sugestões de ordem conceitual serão encaminhadas aos autores, quando necessário. Nesses casos, os artigos, depois de adequados, deverão ser submetidos a nova apreciação. As opiniões emitidas pelos autores dos artigos são de sua exclusiva responsabilidade.
